Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Moon Jeong Lee

Glaucoma Specialist Philadelphia, PA Medical Doctor

NPI 1235674458 CMS profile 11627878

840 Walnut St Ste 1110, Philadelphia, PA 19107

Open in the dashboard

General payments

$2,975

13 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Moon Jeong Lee of Philadelphia, PA is reported in the CMS Open Payments database as having received $2,975 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Glaucoma Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $876 7
2024 General $2,099 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Moon Jeong Lee
  • Glaucoma Specialist median
  • Middle half of Glaucoma Specialist
  • National median

In program year 2025, general payments to Moon Jeong Lee were reported at $876. Among 370 Glaucoma Specialist profiles paid that year, the median was $597 and the middle half received between $244 and $1,607.

Show as a table
Year Moon Jeong Lee Glaucoma Specialist median Middle half National median
2019 $0 $433 $150–$1,170 $163
2020 $0 $242 $74–$693 $114
2021 $0 $324 $122–$936 $132
2022 $0 $399 $121–$1,081 $149
2023 $0 $458 $190–$1,208 $160
2024 $2,099 $558 $215–$1,359 $164
2025 $876 $597 $244–$1,607 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Alcon Vision LLC $2,199 6 payments
  2. Glaukos Corporation $430 4 payments
  3. Johnson & Johnson Surgical Vision, Inc. $145 1 payment
  4. Bausch & Lomb Americas Inc. $112 1 payment
  5. Sight Sciences, Inc. $89 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Travel and Lodging $1,722 3 payments
  2. Food and Beverage $1,253 10 payments
Products named General payments · program years 2024–2025
  1. iDoseTR $234 2 payments
  2. HYDRUS Microstent $148 1 payment
  3. Tecnis IOL $145 1 payment
  4. Centurion $138 1 payment
  5. iDose $137 1 payment
  6. VYZULTA $112 1 payment
  7. Clareon PanOptix Pro $99 1 payment
  8. OMNI SURGICAL SYSTEM $89 1 payment
  9. iStent Trabecular Micro-Bypass System Model iS3 $59 1 payment
  10. iStent infinite $50 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

418

Median for Ophthalmology: 891

Drug cost

$25,862

Median for Ophthalmology: $68,233

Branded share of claims

20.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 15 $14,137
Prednisolone Acetate Generic 166 $8,022
Ketorolac Tromethamine Generic 87 $1,423
Moxifloxacin Moxifloxacin Hcl Brand 57 $844
Brimonidine Tartrate Generic 29 $679
Latanoprost Generic 37 $309
Dorzolamide Hcl Generic 14 $292
Erythromycin Erythromycin Base Brand 13 $157

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$11,388

Medicare's payments for the services billed

Medicare patients

113

Average age 73

Services billed

143

72 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 42%
Chronic kidney disease 29%
Diabetes 28%
Ischemic heart disease 25%
Atrial fibrillation 19%
Depression 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Glaucoma Specialist in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record